Clearbridge Health (SGX:1H3) entered into a binding term sheet with Chen Yan and Lim Chee Yong for the acquisition of Elpis Biopharmaceuticals, according to a Monday filing with the Singapore Exchange.
The total consideration payable is $330 million which will be fully satisfied by the issuance and allotment of new shares in the capital of the company.
The proposed acquisition will be completed within four weeks from the satisfaction of certain conditions.
The target company is engaged in the business of medical research and cell therapies for the treatment of solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.